ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
QBP1 Peptide as a Potential Anti-Amyloidogenic Therapy for Type 2 Diabetes: An In Vitro Study.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Self-assembly and aggregation of human islet amyloid polypeptide (hIAPP, or amylin) into β-sheet-rich oligomers and fibrils have been implicated in pancreatic β-cell dysfunction and failure, contributing to the pathogenesis of type 2 diabetes (T2D). Substantial effort has gone into developing inhibitors, particularly short peptides, capable of targeting hIAPP and disrupting its amyloidogenic process, offering potential therapeutic strategies to prevent or slow T2D progression. Here, we demonstrate the effectiveness of the anti-amyloidogenic peptide QBP1 in halting the conformational conversion of hIAPP into β-structured aggregates, thereby preventing amyloidogenesis and its associated cytotoxicity. First, we evaluated the anti-amyloidogenic effects of QBP1 through cell-free in vitro aggregation experiments, including Thioflavin-T fluorescence, A11/OC dot blotting, and negative-stain electron microscopy. Circular dichroism and nuclear magnetic resonance spectroscopy corroborated that QBP1 delays hIAPP β-sheet formation and oligomerization, respectively, with an efficacy comparable to that of epigallocatechin-3-gallate. Second, we performed cell-based in vitro experiments to investigate cytoprotection in INS-1E β-cells by fusing QBP1 to the cell-penetrating peptide penetratin (Antp-QBP1). Viability assays, immunocytochemistry, and gene expression analysis showed that under amyloidogenic stress Antp-QBP1 preserves β-cell viability and metabolic homeostasis by preventing the formation of early toxic hIAPP intermediates. Finally, in silico experiments using molecular dynamics simulations revealed stable QBP1-hIAPP interactions mediated by van der Waals forces and π-H contacts involving hydrophobic and aromatic residues (e.g., W, F), supported by favorable non-polar solvation and structural complementarity. Taken together, these findings identify QBP1 as a promising candidate for strategies aimed at reducing islet amyloid burden and preserving β-cell integrity in T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.